Two Potential Drug Targets Identified in Cervical Cancer Trial
NRG Oncology
ARID1A and PIK3CA could serve as potential targets for drug development
Articles by NRG Oncology
NRG Oncology Launches FORTE, a Colorectal Cancer Prevention Clinical Trial
NRG Oncology
FORTE is a large, randomized trial of surveillance colonoscopy for participants with one or two small benign polyps